AI Article Synopsis
- Psycho-behavioral studies indicate that sympathetic skin responses (SSR) correlate with emotional reactions, particularly in patients with Social Anxiety Disorder (SAD), who show heightened SSR linked to empathy and alexithymia.
- The study involved SAD patients and a control group, utilizing various scales and tests to measure social anxiety, depression, emotional understanding, and SSR in response to visual emotional stimuli.
- Results revealed that SAD patients exhibited more SSR to negative stimuli and had higher rates of alexithymic traits, suggesting that these factors could amplify their sympathetic sensitivity, necessitating further research for effective treatment approaches.
Article Abstract
Introduction: Psycho-behavioral studies have shown that sympathetic skin response (SSR), which is an indicator of sympathetic function, is associated with emotional responses. It has been reported that SSR, which is claimed to be a biological indicator of empathy, has increased in Social Anxiety Disorder (SAD) patients. The aim of this study was to evaluate the relationship between SSR and alexithymia, empathy in patients with SAD.
Method: SAD patients and control group were applied Liebowitz Social Anxiety Scale, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Toronto Alexithymia Scale, Empathy Quotient, Facial Emotion Identification and Discrimination tests (FID, FDSC); during the application FID, SSR were measured. The relationship between alexithymia and empathy levels were investigated.
Results: The number of SSR was higher in all visual stimuli of SAD patients (11.13±3.01) compared to the control group (7.4±3.57). More autonomous activity to negative stimuli (SAD: 10.55±2.82, control: 6.36±3.64), sensitivity to positive stimuli (SAD: 0.58±0.69, control: 1.03±0.8) was less than control group. While 41.7% of SAD patients had alexithymic features, 36.1% were diagnosed with depressive disorder.
Conclusion: It was thought that depressive and alexithymic features may have contributed to increased sympathetic sensitivity to negative stimuli in SAD patients. Further studies are needed to examine the effects of this situation on the selection and creation of the treatment modalities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024831 | PMC |
| http://dx.doi.org/10.29399/npa.24719 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood biomarker profiles in autopsy‐diagnosed carriers of different PSEN1 mutations relative to sporadic Alzheimer’s disease and controls.
Alzheimers Dement
December 2024
University of Pittsburgh, Pittsburgh, PA, USA
Background: Specific PSEN1 mutations cause early‐onset AD but their effects on blood biomarker levels are unknown. We evaluated autopsy‐confirmed individuals affected by six different PSEN1 mutations; two of known (L381V, C410Y) and three (A426P/E318G, M233L, and V261I) of unknown pathogenic status. The sixth patient had Autosomal Dominant AD (ADAD) not yet genotyped.
View Article and Find Full Text PDFDiagnosis of Alzheimer’s disease‐ Analysis of cross‐species biomarkers.
Alzheimers Dement
December 2024
Yale School of Medicine, New haven, CT, USA
Background: Alzheimer disease (AD) is a heterogeneous multifactorial neurodegenerative disorder pathologically characterized by Aβ plaques, NFT, neuroinflammation, and synaptic and neuronal loss. The nature of most sAD cases strongly argues for an environmental link. The prominent pathological manifestations in AD patients are abnormal levels of Aβ 1‐42 (Aβ42), total tau (t‐tau) and p‐tau in brain and biofluids.
View Article and Find Full Text PDFDevelopment of Xanamem, an isoform 1 specific inhibitor of 11‐βHSD, as a procognitive and disease modifying treatment for mild/moderate Alzheimer’s disease. A pharmacodynamic and biomarker driven approach.
Alzheimers Dement
December 2024
Actinogen Medical, Sydney, Australia
Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS‐specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem’s clinical pharmacology, including the approach to dose selection and proof‐of‐concept studies.
View Article and Find Full Text PDFThe TIE‐93 : a cross‐cultural facial emotion recognition in French and North African Alzheimer’s dementia patients.
Alzheimers Dement
December 2024
Université de Paris Descartes, Paris, Paris, France
Background: Facial emotion recognition testing in Alzheimer’s disease (AD) patients has been identified as key for early detection and as a marker for disease progression. Emotion recognition remains one of the most difficult domains to assess in culturally diverse populations due to a lack of culturally adapted tools. This study assessed the feasibility of a cross‐cultural test for emotion recognition, the TIE‐93, in French and North African populations living in France.
View Article and Find Full Text PDFIntegration of a Digital Cognitive Assessment Tool in a Primary Care Setting.
Alzheimers Dement
December 2024
UMass Chan Medical School, Worcester, MA, USA
Background: Almost all primary care providers (PCPs) believe screening for mild cognitive impairment (MCI) and dementia in older patients is important. However, there are significant barriers in primary care, including low provider confidence in their assessment skills, time constraints, competing priorities, and poor financial incentives. Consequently, PCPs report conducting cognitive assessments for less than half of patients over 60 years of age.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!